Displaying drugs 11101 - 11125 of 11850 in total
Orticumab
Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).
Investigational
Matched Description: … Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab …
BNT111
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
Matched Description: … It consists of a fixed combination of mRNA-encoded, tumor-associated antigens. …
PBGM01
PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme.
Investigational
Matched Description: … PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human …
Refametinib
Investigational
Phosphonotyrosine
An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis. [PubChem]
Experimental
Matched Description: … Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly …
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
Matched Description: … WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin …
Indoprofen
A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.
Withdrawn
Matched Description: … A drug that has analgesic and anti-inflammatory properties. …
PF-232798
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Matched Description: … PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple …
Fenpyroximate
Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania).
Investigational
Matched Description: … clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a …
Ladostigil
Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Investigational
Matched Description: … Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety …
Lazertinib
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Investigational
Matched Description: … Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib …
Veliflapon
Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).
Investigational
Matched Description: … clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a …
Nadecnemab
Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).
Investigational
Matched Description: … Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and …
Maplirpacept
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory …
BEA-17
BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. It is under investigation for the treatment of glioblastoma.
Investigational
Matched Description: … BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. …
XL820
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
Matched Description: … XL820 is a solid. ... receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a …
Sparteine
Sparteine is a plant alkaloid derived from Cytisus scoparius and Lupinus mutabilis which may chelate calcium and magnesium. It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one...
Experimental
Withdrawn
Matched Description: … It is a sodium channel blocker, so it falls in the category of class 1a antiarrhythmic agents. ... Sparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate …
Cirazoline
Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.
Cirazoline has also been shown to decrease food...
Experimental
Matched Description: … Cirazoline acts on a number of α adrenergic receptors. ... It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. …
SCB-2019
SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture.
The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a...
Investigational
Matched Description: … SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID ... As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908 …
N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide
N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide is a solid. This compound belongs to the penicillins. These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting from the sulfur atom at position 1]. This...
Experimental
Matched Description: … organic compounds containing the penicillin core structure, which is structurally characterized by a ... dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide is a …
Gam-COVID-Vac
Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both...
Investigational
Matched Description: … The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus ... The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac ... Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a …
XAV-19
XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability...
Investigational
Matched Description: … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody ... As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety ... Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University …
Displaying drugs 11101 - 11125 of 11850 in total